Loading...
Loading...
Goldman Sachs maintained its Covidien
COV Buy rating in a research report published today. Goldman Sachs has a $56 price target on Covidien shares.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Analyst RatingsGoldman Sachs
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
